Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Merck Receives Subpoena Related to Selling Three Medicines

Merck & Co., the second-largest U.S. drugmaker, received a subpoena from the Department of Justice related to the sales of cancer and antiviral drugs.

The U.S. department asked for details of the marketing and selling of Temodar, PegIntron and Intron A, from January 1, 2004 to the present “in a federal health-care investigation,” Merck said today in a filing.

“This is the first disclosure of this matter,” Ronald Rogers, a spokesman for Whitehouse Station, New Jersey-based Merck, said in an e-mail. The drugmaker is cooperating with the investigation, Rogers said, declining to provide additional information.

Temodar, used to treat brain cancer, accounted for $1.07 billion in sales last year. Intron A for cancer and PegIntron for hepatitis C together generated $946 million in sales.

Merck dropped $1.77 cents, or 5.6 percent, to $29.94 at 4:00 p.m. in New York Stock Exchange composite trading, the lowest price since August 2009. The shares have declined 17 percent this year.

Pfizer Inc. is the biggest U.S. drugmaker.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.